Osteitis fibrosa cystica and secondary hyperparathyroidism in multiple myeloma.
Bains
Margaret A
MA
Department of Haematology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. margaret.bains@rdehc-tr.swest.nhs.uk
Pardoe
Linda E
LE
Rudin
Claudius E
CE
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000473:pathology*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*; D010002:Osteitis Fibrosa Cystica / Q000188:drug therapy / Q000473:pathology*; D010010:Osteoclasts / Q000473:pathology; D000077268:Pamidronate; D014807:Vitamin D / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000188:drug therapy / Q000473:pathology
D000970:Antineoplastic Agents; D004164:Diphosphonates; D014807:Vitamin D; D000077268:Pamidronate